Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
ValiRx plc ( (GB:VAL) ) has issued an update.
ValiRx plc has announced a change in its major shareholdings, with Mark Eccleston now holding a 6.08% voting rights position, including shares acquired through OncoLytika Ltd and Annette Williams. This adjustment in shareholding is part of a recent subscription, with Eccleston and OncoLytika Ltd subscribing to additional ordinary shares, marking a strategic movement in the company’s shareholder distribution. This shift could potentially impact ValiRx’s governance and future financing strategies.
More about ValiRx plc
ValiRx plc operates in the biotechnology industry, focusing on developing innovative treatments for cancer and related diseases. The company is involved in the research and development of therapeutic drugs and diagnostic technologies, aiming to address unmet medical needs in oncology.
YTD Price Performance: -3.85%
Average Trading Volume: 7,009,076
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.81M
See more insights into VAL stock on TipRanks’ Stock Analysis page.
